From regulatory cuts to lower interest rates, this year is shaping up to be ripe for mergers and acquisitions.

SpaceX has confirmed a target IPO date of 2026. The company may reach an IPO valuation of $1.5 trillion. At that price, SpaceX will sell for more than 60x current-year sales. Where to invest $1,000 ...

Elon Musk is signaling a potential SpaceX IPO that could value the company between $1.5 trillion and $2 trillion, with an initial public offering size near $30 billion. A SpaceX listing could reignite ...

NEW YORK, Dec 19 (Reuters) - AI chip maker Cerebras Systems is preparing to file for a U.S. initial public offering as soon as next week, targeting a second-quarter 2026 listing, people familiar with ...

Billionaire investor Bill Ackman pitched an innovative approach to taking SpaceX (SPACE) public through a merger with Pershing Square SPARC Holdings. Ackman's plan would distribute special purpose ...

2026 is already looking to be a special year for the tech industry, as the AI-loving market braces for three major tech IPOs. Three tech giants, SpaceX, Anthropic, and OpenAI, are reportedly eyeing a ...

Chinese chipmakers are rushing to the IPO market, raising funds that are key to the nation’s goal of technological self-reliance and winning the global race on artificial intelligence. The surge in ...

NEW YORK, Dec 19 (Reuters) - Morgan Stanley is emerging as a leading contender for a key role in SpaceX's blockbuster initial public offering, as the bank's close ties to CEO Elon Musk give it an edge ...

SpaceX employees have been told to keep mum about the company’s plans for a possible IPO, but that isn’t stopping Wall Street from buzzing about what could become its biggest payday in years, On The ...

The banner across Medline's homepage today reads, "We're public." It's a bit of an understatement. The Northfield-based global medical supplies company on Dec. 16 offered about 216 million shares at ...

Big Pharma-backed Aktis Oncology has announced plans to go public, in the latest encouraging sign for those betting on a resurgence in biotech IPOs next year. Aktis saw the likes of Bristol Myers ...

Fannie Mae and Freddie Mac are poised for a public IPO, likely in Q1 next year, following administration and Treasury guidance. Junior preferred shares, such as FNMAS, offer anti-dilution protection ...